mp.weixin.qq.com·· 9 hours agoPickScore85
Kelun-Biotech sac-TMT Second-Line Lung Cancer Study OptiTROP-Lung04 Reports Final OS of 25.9 Months, Extending Survival 8.5 Months Over Platinum Doublet Chemotherapy
In brief
Kelun-Biotech's sac-TMT showed a median overall survival of 25.9 months in the final OS results of the OptiTROP-Lung04 study, presented at this year's ESMO congress, an 8.5-month improvement over platinum-based doublet chemotherapy in second-line lung cancer. Earlier, OptiTROP-Lung03 showed that in patients who progressed after EGFR-TKI and platinum-based chemotherapy, sac-TMT significantly prolonged survival versus docetaxel, with dual PFS and OS benefit. The two studies cover later-line and second-line lung cancer treatment, respectively.
Why it matters
The article lists key survival results and comparators for sac-TMT in later-line and second-line studies, aiding comparison of benefit across treatment stages.
Source: mp.weixin.qq.com · mp.weixin.qq.com